Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Zevra Therapeutics (ZVRA – Research Report). The associated ...
Precigen’s Strategic Advancements and FDA Alignment Bolster Buy Rating
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...
Medicare Special Needs Plans Are Booming In Popularity. Are You Missing Out?
Medicare Advantage Special Needs Plans now make up more than a quarter of all enrollments. Learn more about what they are and ...
The Register-Herald1d
WVU forensic science research responds to DEA need for faster, better identification of drugs like fentanyl
Fentanyl analogs are so chemically similar that forensic analysis can mistake one drug for another, but there are important ...
Johnson & Johnson: Tracking Well Above The Industry
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA
Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...
ICU's Joint Venture With Otsuka Should Help Improve Its Margin Profile
Recent quality and operational issues at Smiths, which originated before it was purchased, greatly reduced ICU’s gross margin after the acquisition. These issues have required additional spending to ...
H.C. Wainwright Maintains ‘Buy’ Rating on Spectral AI, Inc. (MDAI) with $3.50 Price Target After Strong Q3 Results and Regulatory Progress
We recently compiled a list of the 15 AI News That Should Not Be Ignored. In this article, we are going to take a look at ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Alzheimer’s caregivers need updated drug rules to give families more time and peace | Opinion
Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...